Merck Stock Forecast for 2023 - 2025 - 2030
Updated on 09/25/2023
Merck Stock Forecast and Price Target
The average price target of $118.00 for Merck's stock set by fiveteen distinguished analysts in recent weeks would represent a potential upside of approximately 11.49% from the last closing price in September, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $136.00 and a low estimate of $97.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.
11.49% Upside
Merck Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Merck's Price has grown, increasing from $71.99 to $83.50 – a growth of 15.99%. The next year looks promising for Merck, with analysts predicting Fair Value of $100.42 – an increase of 20.27%. Over the next eight years, experts anticipate that Merck's Fair Value will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | $179.95 | 12.63% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$32.98 | $44.13 | 59.64% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$59.16 | $80.99 | 40.30% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$350.67 | $384.26 | -7.04% |
Merck Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Merck's Revenue has grown, increasing from $46.84B to $48.70B – a growth of 3.98%. The next year looks promising for Merck, with analysts predicting Revenue of $55.63B – an increase of 14.21%. Over the next eight years, experts anticipate that Merck's Revenue will grow at a rate of 5.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$177.72 | $209.70 | 15.35% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$834.64 | $796.73 | -6.31% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.50 | $60.73 | 54.67% |
Merck Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Merck's Dividend per Share has grown by 18.18%, from $2.20 to $2.60. For the next year, analysts are expecting Dividend per Share to reach $3.01 – an increase of 15.77%. Over the next eight years, experts predict that Dividend per Share will grow by 23.08%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$170.77 | $244.18 | 46.98% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.71 | $13.70 | 39.03% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$224.06 | $280.69 | 31.66% |
Merck Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Merck's Free Cash Flow has fallen from $9.97B to $9.66B – a 3.07% decrease. For next year, analysts predict Free Cash Flow of $16.98B, which would mean an increase of 75.75%. Over the next eight years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent Inc | Hold |
15
|
$45.82 | $83.92 | 59.32% |
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$42.67 | $52.42 | 17.18% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$126.67 | $163.67 | 29.47% |
Merck Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Merck's Net Income has grown from $9.84B to $13.05B – a 32.57% increase. Next year, analysts are expecting Net Income to reach $18.11B – an increase of 38.81%. Over the next eight years, the forecast is for Net Income to grow by 29.43%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Hold |
16
|
$19.48 | $37.00 | 30.90% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$30.00 | $62.67 | 100.00% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$8.97 | $73.38 | 111.82% |
Merck EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Merck's EBITDA has grown by 3.31%, rising from $18.37B to $18.98B. For next year, analysts predict EBITDA of $23.74B, which would mean an increase of 25.07%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to $18.25B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£21.51 | £3.79 | -77.96% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$32.82 | $79.67 | 137.66% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$32.32 | $0.00 | -8.73% |
Merck EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Merck's EBIT has grown, rising from $14.95B to $15.86B – a growth of 6.05%. In the next year, analysts believe that EBIT will reach $21.25B – an increase of 34.03%. For the next eight years, the forecast is for EBIT to grow by 23.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.96 | $41.00 | -4.26% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$8.53 | $12.60 | 46.54% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | $35.50 | 13.11% |
Merck EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Merck's EPS has grown, increasing from $5.19 to $6.02 – a growth of 15.99%. The next year looks promising for Merck, with analysts predicting EPS of $7.24 – an increase of 20.27%. Over the next eight years, experts anticipate that Merck's EPS will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$58.86 | $195.43 | 169.28% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$150.96 | $170.08 | 15.92% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$59.75 | $104.00 | -4.60% |